|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, SMA+ CAFs are more prevalent in NSCLC tumors of higher stages and lymphonodal positive NSCLC.
|
31760702 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The ipsilateral hemisphere with MBD-EPO (vs. MBD-only) showed significantly increased vessels (RECA-1, p = 0.0182) and their maturation (RECA-1/α-SMA, p = 0.0046), with upregulation of tumor growth factor-β1 (Tgf-β1, p = 0.037) and matrix metalloproteinase-2 (Mmp-2, p = 0.0488).
|
31344491 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In vivo, EREG expression in stroma fibroblasts promoted tumor growth with high stromal α-SMA, phospho-JAK2/STAT3, and IL-6 expression and upregulated EMT in HSC3 cells.
|
31234944 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of tumor tissues suggest that the treatment inhibits tumor stroma (α-SMA, Desmin and Hyluronic Acid) and induces changes in cell stiffness, as measured via Atomic Force Microscopy.
|
30999154 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Retlap enabled us to identify and secure the roots of the celiac axis and SMA easily despite the advanced tumor.
|
30851918 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although the tumor location is unusual (but head and neck seated), most of the other clinical, morphologic, immunophenotypic (focal combined expression of S100 protein, SMA, desmin, and myogenin) and oncogenic data suggest that this biphenotypic "oropharyngeal" sarcoma is closely related to the biphenotypic SNS spectrum.
|
29266774 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of α‑SMA, glucose transporter 1, hexokinase 2, lactic dehydrogenase and mono‑carboxylate transporter (MCT) 4 were significantly overexpressed in activated fibroblasts, while IL‑1β and MCT1 were upregulated in OSCC cells, indicating enhanced glycolysis in cells of the tumor stroma and a lactate shuttle to the tumor cells.
|
29207019 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SMA-tDodSNO in combination with SMA-Dox resulted in a statistically significant 4.7-fold reduction in the tumor volume (<i>P</i><0.001 vs control), without causing significant toxicity as monitored through body weight loss.
|
30538458 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Most of the tumors were variably positive for CD31 (7/8), CAM5.2 (2/3), and SMA (4/6). t(7;19)(q22;q13) fusion pattern was detected in 3 cases (5 tumors) with cutaneous and multifocal PHE.
|
29104110 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In vivo, Lnc-CAF knockdown restricted tumor growth and was associated with decreased Ki-67 expression and α-SMA+ CAF in the stroma.
|
29346528 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Near-infrared (NIR) imaging of CA IX-SMA-TPGS-S0456 in Evr-res A498 RCC model exhibited significant accumulation of CA IX-oligomer in tumor core with >3-fold higher tumor uptake as compared to control.
|
30179778 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although combination therapy increases E-cadherin, the increase of N-cadherin and α-SMA in tumor tissue was also observed.
|
30234992 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SMA-WIN in combination with Doxo showed therapeutic efficacy and was able to reduce the tumor volume of TNBC murine model drastically.
|
30367922 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Inhibition of TGF-β1 by TGF-β1 neutralizing antibody decreased the EMT-associated gene expression and NBT-II cell invasion, suggesting that α-SMA+Fs can induce tumor EMT through TGF-β1.
|
29934361 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Patients who did not develop tumor recurrence up to 4 years after LT showed a reversed expression pattern of fibrogenic markers with decreased levels of β-PDGFR, Collagen 1, and α-SMA in their non-tumorous liver tissue versus the tumor tissue at time of LT as assessed in protein and mRNA expression analysis.
|
28729525 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, mouse models showed that baicalein reduced the tumor volume and greatly reduced the tumor growth rate in the early stages of tumor progression, and the baicalein-treated groups had significantly reduced expression of CD31 (endothelial cell marker) and α-SMA (mural cell marker) in the tumors, indicating that baicalein inhibits tumor angiogenesis by disrupting tumor vasculature development.
|
29048641 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The assessment of SPA growth in nude mice indicated an absence of tumour growth in the SPA-XT-II group (in which the XT-II gene was silenced), whereas SPA growth was observed in the other two groups (in which the XT-II gene was not silenced), and the tumour tissue was positive for the human S-100 protein, α-SMA and CK8&18.
|
27732748 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The α-SMA-positive fibroblast and collagen within the tumor decreased significantly after combination treatment.
|
28414916 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Data on the EM were compared with clinicopathological findings, including stromal features represented by Azan staining and the α-SMA positive area ratio of the tumor area.
|
26083008 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, in tumor samples from 50 colon cancer patients, SNAI1 expression was associated with expression of other CAF markers, such as α-SMA and fibroblast activation protein.
|
24242829 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, if the tumor is negative for KIT, CD34, S-100, and SMA, a definitive diagnosis is often challenging.
|
24379641 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of miR-92a was therefore characterized in 144 invasive breast cancer samples using in situ hybridization and related to clinico-pathological data as well as to selected key properties of the tumour stroma, including the presence of macrophages (CD68) and cancer activated fibroblasts (alpha-SMA).
|
22563438 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Towards this end, three classes of markers were investigated: cancer-associated fibroblasts (CAFs; α-SMA positivity) as a representative of the tumor microenvironment, maspin (mammary serine protease inhibitor) as a tumor marker likely to be modulated by factors within the tumor microenvironment, and DNA content and Ki-67 labeling index as inbuilt tumor markers in 128 cases of MTSCC using immunohistochemistry and image cytometry.
|
21112238 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mice were killed at 6 weeks, livers and kidneys weighed, and tumor removed for immunohistochemical staining for endothelial cells (CD34), pericytes (alpha-SMA), apoptosis (TUNEL [terminal deoxynucleotidyl transferase dUTP nick-end labeling]), and diI-labeled NPCs.
|
18726131 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumours were classified into two groups: (1) tumours with basal phenotype [expressing one or both basal markers (CK5/6 and/or CK14)] and (2) tumours with myoepithelial phenotype (expressing SMA and/or p63).
|
16429394 |
2006 |